Methadone Maintenance Dosing and Withdrawal Management
Maintenance Dosing
For opioid use disorder maintenance, methadone should be titrated to 80–120 mg daily, which represents the dose range most consistently associated with treatment retention and suppression of illicit opioid use. 1
Induction Protocol
- Initial dose: 20–30 mg on day 1, administered under supervision when withdrawal symptoms are present but no signs of sedation or intoxication exist 1
- Maximum first-day dose: 40 mg total (including any same-day adjustments made 2–4 hours after initial dosing when peak levels are reached) 1
- Week 1 titration: Adjust doses based on withdrawal control at expected peak activity (2–4 hours post-dose), with cautious increases to avoid cumulative toxicity 1
- Steady-state warning: Full analgesic effects and steady-state plasma concentrations typically require 3–5 days due to methadone's long half-life (8–59 hours vs morphine's 1–5 hours) 1
Target Maintenance Dose
- Standard range: 80–120 mg daily achieves clinical stability (24-hour symptom prevention, reduced cravings, blockade of euphoric effects from illicit opioids) in most patients 1
- Higher doses (>100 mg) may be necessary for patients with continued illicit opioid use despite adequate trial of standard dosing 2
- Dose individualization: Effective doses range widely (1.5–191 mg in one study), influenced by psychiatric comorbidity (PTSD, depression), prior detoxification attempts, and regional heroin purity 3
Special Populations
Pregnancy: Physiologic changes (increased volume of distribution, progesterone-induced CYP450 metabolism) often necessitate dose increases or split dosing during second and third trimesters 4. Some patients may require substantially higher doses (up to 900 mg daily documented in cases of rapid metabolism) 5.
Patients on methadone for pain: Once-daily dosing provides inadequate analgesia; methadone's analgesic duration is only 6–8 hours despite its 30-hour half-life 6. Split-dosing (dividing total daily dose into multiple administrations) is required for pain control 6.
Withdrawal Management (Detoxification)
Methadone withdrawal should proceed at ≤10% dose reductions every 10–14 days in outpatient settings, with total taper duration of 14–20 weeks minimum to minimize withdrawal severity and relapse risk. 7, 1
Outpatient Taper Protocol
- Reduction rate: 10% of established dose every 10–14 days (e.g., 50→45→40→35→30→25→20→15→10→5 mg, then discontinue) 7, 1
- Minimum duration: 14–20 weeks for patients on stable maintenance 7
- Alternative slower taper: 3% of initial dose per week reduces dropout rates and illicit drug use compared to 10% weekly reductions 8
Inpatient Taper Protocol
- Reduction rate: 20% of total daily dose per day under close monitoring 7, 1
- Short-term detoxification: Stabilize at ~40 mg for 2–3 days, then reduce daily or every 2 days while maintaining tolerable withdrawal symptoms 1
Adjunctive Pharmacotherapy for Withdrawal
α2-Agonists (start at low doses, titrate carefully):
- Clonidine: Reduces withdrawal intensity but carries orthostatic hypotension risk 7
- Lofexidine: FDA-approved for opioid withdrawal with safer hemodynamic profile than clonidine 7
- Tizanidine: Modest withdrawal relief with lower hypotension incidence 7
Symptomatic management:
- Antiemetics (promethazine) for nausea/vomiting 7
- Benzodiazepines (short-term) for anxiety, muscle cramps, catecholamine surge 7
- Loperamide for diarrhea (caution against high-dose misuse due to arrhythmia risk) 7
- Sleep/anxiety agents: Trazodone, tricyclic antidepressants, gabapentin, or mirtazapine 7
Transition to Buprenorphine
- Pre-initiation requirement: Patient must be in mild opioid withdrawal (Clinical Opiate Withdrawal Scale >8) before first buprenorphine dose to avoid precipitated withdrawal 7
- Initial dosing: 4–8 mg sublingual buprenorphine, titrating toward target of ~16 mg daily 7
- Comparative effectiveness: Buprenorphine and methadone demonstrate similar success rates for opioid detoxification 7
Critical Pitfalls to Avoid
Conversion errors: Rigid equianalgesic tables should not be applied to methadone due to incomplete cross-tolerance and variable potency in chronic use 7. Deaths have occurred during conversion from other high-dose opioids to methadone 1.
Rapid titration: Methadone should not be titrated more frequently than every 5–7 days; significant sedation or marked pain improvement before day 5 indicates excessive dosing and risk of respiratory depression by days 5–7 9.
Loss of tolerance: Consider reduced tolerance in any patient who has not taken opioids for >5 days; initial doses should be lower 1.
QTc prolongation: Methadone prolongs the QTc interval; caution if QTc 450–499 msec, strongly consider alternative therapy if ≥500 msec 4.
Protracted withdrawal: Patients may experience months-long dysphoria, irritability, insomnia, and anhedonia after plasma clearance, requiring ongoing psychosocial support 7.
Post-Detoxification Care
- Overdose prevention: Prescribe take-home naloxone and provide overdose education to all patients completing detoxification 7
- Infectious disease screening: Offer hepatitis C and HIV screening as part of comprehensive post-detox care 7
- Relapse risk counseling: Patients should be informed of the high relapse risk associated with methadone discontinuation 1